CDXC ChromaDex Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: CDXC

Price (delayed)

$8.92

Market cap

$605.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.35

Enterprise value

$562.74M

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create ...

Highlights
The equity has surged by 167% since the previous quarter and by 165% year-on-year
CDXC's quick ratio has surged by 112% since the previous quarter and by 110% year-on-year
The company's EPS rose by 31% YoY but it fell by 6% QoQ
The company's net income rose by 28% YoY but it fell by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://chromadex.com/default.aspx
Peers: EXEL SGMO

Key stats

What are the main financial stats of CDXC
Market
Shares outstanding
67.93M
Market cap
$605.96M
Enterprise value
$562.74M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.58
Price to sales (P/S)
9.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.44
Earnings
Revenue
$59.6M
EBIT
-$21.33M
EBITDA
-$19.77M
Free cash flow
-$10.94M
Per share
EPS
-$0.35
Free cash flow per share
-$0.17
Book value per share
$0.66
Revenue per share
$0.93
TBVPS
$1.06
Balance sheet
Total assets
$68.99M
Total liabilities
$25.16M
Debt
$1.47M
Equity
$43.83M
Working capital
$43.46M
Liquidity
Debt to equity
0.03
Current ratio
3.2
Quick ratio
2.5
Net debt/EBITDA
2.19
Margins
EBITDA margin
-33.2%
Gross margin
60.7%
Net margin
-35.9%
Operating margin
-35.8%
Efficiency
Return on assets
-45.8%
Return on equity
-84.5%
Return on invested capital
-310%
Return on capital employed
-43.3%
Return on sales
-35.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDXC stock price

How has the ChromaDex stock price performed over time
Intraday
2.65%
1 week
-6.3%
1 month
-5.21%
1 year
76.28%
YTD
85.83%
QTD
-9.53%

Financial performance

How have ChromaDex's revenue and profit performed over time
Revenue
$59.6M
Gross profit
$36.2M
Operating income
-$21.33M
Net income
-$21.4M
Gross margin
60.7%
Net margin
-35.9%
ChromaDex's net margin has increased by 39% YoY but it has decreased by 7% from the previous quarter
CDXC's operating margin is up by 37% year-on-year but it is down by 7% since the previous quarter
The company's net income rose by 28% YoY but it fell by 7% QoQ
ChromaDex's operating income has increased by 26% YoY but it has decreased by 7% QoQ

Growth

What is ChromaDex's growth rate over time

Valuation

What is ChromaDex stock price valuation
P/E
N/A
P/B
13.58
P/S
9.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.44
The company's EPS rose by 31% YoY but it fell by 6% QoQ
The equity has surged by 167% since the previous quarter and by 165% year-on-year
CDXC's price to book (P/B) is 34% higher than its 5-year quarterly average of 10.1 but 6% lower than its last 4 quarters average of 14.5
CDXC's price to sales (P/S) is 57% higher than its last 4 quarters average of 6.1 and 33% higher than its 5-year quarterly average of 7.2
The revenue has grown by 18% YoY

Efficiency

How efficient is ChromaDex business performance
The company's return on equity rose by 44% YoY and by 21% QoQ
The company's return on sales rose by 37% YoY but it fell by 7% QoQ
ChromaDex's return on assets has increased by 37% YoY and by 12% QoQ
CDXC's return on invested capital is down by 19% since the previous quarter and by 7% year-on-year

Dividends

What is CDXC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDXC.

Financial health

How did ChromaDex financials performed over time
The total assets is 174% more than the total liabilities
CDXC's quick ratio has surged by 112% since the previous quarter and by 110% year-on-year
The total assets has soared by 94% YoY and by 80% from the previous quarter
ChromaDex's debt is 97% less than its equity
The equity has surged by 167% since the previous quarter and by 165% year-on-year
CDXC's debt to equity has dropped by 70% since the previous quarter and by 67% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.